{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:11:40Z","timestamp":1771661500942,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Servier Deutschland GmbH","award":["IC4-05154-173-DEU"],"award-info":[{"award-number":["IC4-05154-173-DEU"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>In this prospective, multicenter, observational cohort study, the effectiveness and tolerability of the first fixed-dose combination (FDC) formulation of the selective heart rate reducing agent ivabradine and the beta-blocker metoprolol was evaluated in stable angina pectoris (AP) patients in a clinical practice setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Stable AP outpatients received a FDC of ivabradine and metoprolol (b.i.d.) for 4\u00a0months, in addition to cardiovascular standard therapy. Resting heart rate (HR), number of angina attacks, short-acting nitrate consumption, severity of symptoms (assessed by patient judgment and documented by CCS score) and tolerability were documented. Medication adherence was assessed by a modified four-item Morisky questionnaire. Descriptive statistics were performed on all data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 747 stable AP patients (mean age, 66.4\u00a0years, 62% male, 50% and 31% with previous PCI and myocardial infarction, respectively) were included. Apart from ivabradine and beta-blockers as free combination, most frequently used concomitant standard medications at baseline were aspirin (68%), statins (71%), ACEI\/AT1-blockers (76%), diuretics (35%), and calcium antagonists (15%). Highly prevalent comorbidities were hypertension (86%), hyperlipidemia (65%), and diabetes (35%). After 4\u00a0months, switch to treatment with the FDC was associated with a significant reduction in mean HR by 10\u00a0bpm. Proportion of patients with\u00a0\u2265\u00a01 angina attacks\/week decreased from 38 to 7%. Patients in CCS class 1 increased (25 to 63%), while they decreased in CCS class 3 (19 to 5%). Medication adherence was also significantly improved (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001 for all changes from baseline). Mostly mild adverse events were documented in 5.4% of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In these stable AP patients in a real-life setting, treatment with a FDC of ivabradine and metoprolol was associated with reduced HR and angina symptoms, while exercise capacity (CCS score) was improved. These effects may be mainly mediated by the increased medication adherence of patients observed with use of the FDC formulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Funding<\/jats:title>\n                <jats:p>Servier<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p>ISRCTN51906157<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40119-017-0099-1","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T09:14:05Z","timestamp":1510046045000},"page":"239-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of Stable Angina with a New Fixed-Dose Combination of Ivabradine and Metoprolol: Effectiveness and Tolerability in Routine Clinical Practice"],"prefix":"10.1007","volume":"6","clinical-trial-number":[{"clinical-trial-number":"isrctn51906157","registry":"10.18810\/isrctn"}],"author":[{"given":"Dimitar","family":"Divchev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"St\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the study investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,7]]},"reference":[{"key":"99_CR1","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/sj.bjp.0707673","volume":"153","author":"G Heusch","year":"2008","unstructured":"Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008;153:1589\u2013601.","journal-title":"Br J Pharmacol"},{"key":"99_CR2","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht310.P4876","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949\u20133003.","journal-title":"Eur Heart J"},{"key":"99_CR3","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1161\/CIR.0b013e318277d6a0","volume":"126","author":"SD Fihn","year":"2012","unstructured":"Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, et al. 2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354\u2013471.","journal-title":"Circulation"},{"key":"99_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/pgmj.2009.084384","volume":"86","author":"CA Daly","year":"2010","unstructured":"Daly CA, Clemens F, Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM. Inadequate control of heart rate in patients with stable angina: results from the European heart survey. Postgrad Med J. 2010;86:212\u20137.","journal-title":"Postgrad Med J"},{"key":"99_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.amjmed.2004.02.044","volume":"117","author":"FC Wiest","year":"2004","unstructured":"Wiest FC, Bryson CL, Burman M, McDonell MB, Henikoff JG, Fihn SD. Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care setting. Am J Med. 2004;117:234\u201341.","journal-title":"Am J Med"},{"key":"99_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijcard.2014.06.052","volume":"176","author":"M Tendera","year":"2014","unstructured":"Tendera M, Fox K, Ferrari R, Ford I, Greenlaw N, Abergel H, Macarie C, Tardif JC, Vardas P, Zamorano J, Gabriel SP. Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. Int J Cardiol. 2014;176:119\u201324.","journal-title":"Int J Cardiol"},{"issue":"5","key":"99_CR7","doi-asserted-by":"publisher","first-page":"e36284","DOI":"10.1371\/journal.pone.0036284","volume":"7","author":"PG Steg","year":"2012","unstructured":"Steg PG, Ferrari R, Ford I, et al. Heart rate and use of beta blockers in stable outpatients with coronary artery disease. PLoS One. 2012;7(5):e36284.","journal-title":"PLoS One"},{"key":"99_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1185\/030079905X50543","volume":"21","author":"D DiFrancesco","year":"2005","unstructured":"DiFrancesco D. Cardiac pacemaker If current and its inhibition by heart rate-reducing agents. Curr Med Res Opin. 2005;21:1115\u201322.","journal-title":"Curr Med Res Opin"},{"key":"99_CR9","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","volume":"64","author":"D DiFrancesco","year":"2004","unstructured":"DiFrancesco D, Camm AJ. Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs. 2004;64:1757\u201365.","journal-title":"Drugs"},{"key":"99_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1054-3589(10)59003-3","volume":"59","author":"C Thollon","year":"2010","unstructured":"Thollon C, Vilaine JP. I f inhibition in cardiovascular diseases. Adv Pharmacol. 2010;59:53\u201392.","journal-title":"Adv Pharmacol"},{"key":"99_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2016.04.001","volume":"215","author":"PG Camici","year":"2016","unstructured":"Camici PG, Gloekler S, Levy BI, Skalidis E, Tagliamonte E, Vardas P, Heusch G. Ivabradine in chronic stable angina: effects by and beyond heart rate reduction. Int J Cardiol. 2016;215:1\u20136.","journal-title":"Int J Cardiol"},{"key":"99_CR12","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.115.06091","volume":"66","author":"JG Dillinger","year":"2015","unstructured":"Dillinger JG, Maher V, Vitale C, Henry P, Logeart D, Manzo SS, Allee G, Levy BI. Impact of ivabradine on central aortic blood pressure and myocardial perfusion in patients with stable coronary artery disease. Hypertension. 2015;66:1138\u201344.","journal-title":"Hypertension"},{"key":"99_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s12325-015-0237-x","volume":"32","author":"E Tagliamonte","year":"2015","unstructured":"Tagliamonte E, Cirillo T, Rigo F, Astarita C, Coppola A, Romano C, Capuano N. Ivabradine and bisoprolol on Doppler-derived coronary flow velocity reserve in patients with stable coronary artery disease: beyond the heart rate. Adv Ther. 2015;32:757\u201367.","journal-title":"Adv Ther"},{"issue":"1","key":"99_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00392-016-1024-7","volume":"106","author":"F Mangiacapra","year":"2017","unstructured":"Mangiacapra F, Colaiori E, Ricottini E, Balducci F, Creta A, Demartini G, Di Sciascio G. Heart rate reduction by ivabradine for improvement of endothelial function in patients with coronary artery disease: the RIVENDEL study. Clin Res Cardiol. 2017;106(1):69\u201375.","journal-title":"Clin Res Cardiol"},{"key":"99_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/heartjnl-2013-304880","volume":"100","author":"S Gloekler","year":"2014","unstructured":"Gloekler S, Traupe T, Stoller M, Schild D, Steck H, Khattab A, Vogel R, Seiler C. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart. 2014;100:160\u20136.","journal-title":"Heart"},{"key":"99_CR16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","volume":"107","author":"JS Borer","year":"2003","unstructured":"Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I f inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817\u201323.","journal-title":"Circulation"},{"key":"99_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1159\/000108387","volume":"108","author":"L Lopez-Bescos","year":"2007","unstructured":"Lopez-Bescos L, Filipova S, Martos R. Long term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology. 2007;108:387\u201396.","journal-title":"Cardiology"},{"key":"99_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2165\/00003495-200767030-00005","volume":"67","author":"W Ruzyllo","year":"2007","unstructured":"Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67:393\u2013405.","journal-title":"Drugs"},{"key":"99_CR19","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","volume":"26","author":"JC Tardif","year":"2005","unstructured":"Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529\u201336.","journal-title":"Eur Heart J"},{"key":"99_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","volume":"30","author":"JC Tardif","year":"2009","unstructured":"Tardif JC, Ponikowski P, Kahan T. Efficacy of the I f current inhibitor ivabradine in patients with chronic stable angina receiving beta blocker therapy: a 4\u00a0month, randomized, placebo-controlled trial. Eur Heart J. 2009;30:540\u20138.","journal-title":"Eur Heart J"},{"key":"99_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00392-011-0402-4","volume":"101","author":"K Werdan","year":"2012","unstructured":"Werdan K, Ebelt H, Nuding S, H\u00f6pfner F, Hack G, M\u00fcller-Werdan U. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012;101:365\u201373.","journal-title":"Clin Res Cardiol"},{"key":"99_CR22","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ahj.2009.06.008","volume":"158","author":"R K\u00f6ster","year":"2009","unstructured":"K\u00f6ster R, Kaehler J, Meinertz T. Treatment of stable angina pectoris by ivabradine in everyday practice: the REDUCTION study. Am Heart J. 2009;158:e51\u20137.","journal-title":"Am Heart J"},{"key":"99_CR23","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1007\/s12325-016-0377-7","volume":"33","author":"S Perings","year":"2016","unstructured":"Perings S, St\u00f6ckl G, Kelm M. Effectiveness and tolerability of ivabradine with or without concomitant beta-blocker therapy in patients with chronic stable angina in routine clinical practice. Adv Ther. 2016;33:1550\u201364.","journal-title":"Adv Ther"},{"key":"99_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000439584","volume":"133","author":"K Werdan","year":"2016","unstructured":"Werdan K, Ebelt H, Nuding S, H\u00f6pfner F, St\u00f6ckl G, M\u00fcller-Werdan U. Ivabradine in combination with metoprolol improves symptoms and quality of life in patients with stable angina pectoris: a post hoc analysis from the ADDITIONS trial. Cardiology. 2016;133:83\u201390.","journal-title":"Cardiology"},{"key":"99_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000447443","volume":"135","author":"K Werdan","year":"2016","unstructured":"Werdan K, Perings S, K\u00f6ster R, Kelm M, Meinertz T, St\u00f6ckl G, M\u00fcller-Werdan U. Effectiveness of ivabradine treatment in different subpopulations with stable angina in clinical practice: a pooled analysis of observational studies. Cardiology. 2016;135:141\u201350.","journal-title":"Cardiology"},{"key":"99_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ahj.2005.02.038","volume":"151","author":"SP Kulkarni","year":"2006","unstructured":"Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimen. Am Heart J. 2006;151:185\u201391.","journal-title":"Am Heart J"},{"key":"99_CR27","first-page":"814","volume":"171","author":"NK Choudhry","year":"2011","unstructured":"Choudhry NK, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, Shrank WH. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171:814\u201322.","journal-title":"Arch Intern Med"},{"key":"99_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","volume":"24","author":"DE Morisky","year":"1986","unstructured":"Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67\u201374.","journal-title":"Med Care"},{"key":"99_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10557-011-6327-3","volume":"25","author":"E Amosova","year":"2011","unstructured":"Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R. Efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina. Cardiovasc Drugs Ther. 2011;25:531\u20137.","journal-title":"Cardiovasc Drugs Ther"},{"key":"99_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10557-011-6340-6","volume":"25","author":"RW Sy","year":"2011","unstructured":"Sy RW, Freedman SB. Beta-blocker dose uptitration or addition of ivabradine in stable angina: more is not necessarily better. Editorial to: \u2018Efficacy of ivabradine in combination with beta-blocker versus uptitration of betablocker in patients with stable angina\u2019 by E. Amosova et al. Cardiovasc Drugs Ther. 2011;25:501\u20132.","journal-title":"Cardiovasc Drugs Ther"},{"key":"99_CR31","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","volume":"120","author":"S Bangalore","year":"2007","unstructured":"Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713\u20139.","journal-title":"Am J Med"},{"key":"99_CR32","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.clinthera.2007.05.010","volume":"29","author":"V Fung","year":"2007","unstructured":"Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a Medicare population: adherence and systolic blood pressure control. Clin Ther. 2007;29:972\u201384.","journal-title":"Clin Ther"},{"key":"99_CR33","first-page":"673","volume":"4","author":"BV Patel","year":"2008","unstructured":"Patel BV, Leslie RS, Thiebaud P, Nichol MB, Tang SS, Solomon H, Honda D, Foody JM. Adherence with single-pill amlodipine\/atorvastatin vs. a two-pill regimen. Vasc Health Risk Manag. 2008;4:673\u201381.","journal-title":"Vasc Health Risk Manag"},{"key":"99_CR34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1742-1241.2007.01683.x","volume":"62","author":"N Muszbek","year":"2008","unstructured":"Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract. 2008;62:338\u201351.","journal-title":"Int J Clin Pract"},{"key":"99_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijcard.2017.01.018","volume":"232","author":"C Vitale","year":"2017","unstructured":"Vitale C, Fini M, Spoletini I, Lainscak M, Seferovic P, Rosano GMC. Under-representation of elderly and women in clinical trials. Int J Cardiol. 2017;232:216\u201321.","journal-title":"Int J Cardiol"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-017-0099-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-017-0099-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-017-0099-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:22:19Z","timestamp":1628616139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-017-0099-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,7]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1007\/s40119-017-0099-1","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,7]]},"assertion":[{"value":"1 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}